Biologic registries in rheumatology: Lessons learned and expectations for the future

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 329-336

  Elkayam, Ori ^a   Pavelka, Karel ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biological therapy; Europe; Registries; Review; Rheumatoid arthritis; TNFR Fc fusion protein

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CZECH REPUBLIC; DEMOGRAPHY; DENMARK; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; EUROPE; FINLAND; FRANCE; GEOGRAPHY; GERMANY; HUMAN; ITALY; LYMPHOMA; NETHERLANDS; NORWAY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SPAIN; SWEDEN; SWITZERLAND; TUBERCULOSIS; TURKEY (BIRD); UNITED KINGDOM;

EUROPE; HUMANS; REGISTRIES; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84870242760     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.05.009     Document Type: Review

References (64)

1. Kvien T.K. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004, 22:1-12.
2. van der Linden S. Ankylosing spondylitis. Kelley's textbook of rheumatology 2005, WB Saunders Co., Philadelphia. 7th ed.
3. Gladman D.D., Antoni C., Mease P., Clegg D.O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64:ii14-ii17. 10.1136/ard.2004.032482.
4. Harris E.D. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990, 322:1277-1289.
5. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874.
6. Pincus T., Stein C.M. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997, 15:S27-S38.
7. Pincus T. Limitations of randomized clinical trials in chronic diseases: explanations and recommendations. Adv Mind Body Med 2002, 18:14-21.
8. Curtis J.R., Jain A., Askling J., Bridges S.L., Carmona L., Dixon W., et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010, 40:2-14. [e1].
9. Geborek P., Crnkic M., Petersson I.F., Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798.
10. Kremer J., Gibofsky A., Greenberg J.D. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 2008, 20:123-130.
11. Kievit W., Fransen J., Adang E.M., den Broeder A.A., Bernelot Moens H.J., Visser H., et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007, 66:1473-1478.
12. Weaver A.L., Lautzenheiser R.L., Schiff M.H., Gibofsky A., Perruquet J.L., Luetkemeyer J., et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006, 22:185-198.
13. Silman A., Klareskog L., Breedveld F., Bresnihan B., Maini R., Van Riel P., et al. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Ann Rheum Dis 2000, 59:419-420.
14. Zink A., Askling J., Dixon W.G., Klareskog L., Silman A.J., Symmons D.P. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009, 68:1240-1246.
15. Gomez-Reino J.J., Carmona L., Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761. 10.1002/art.22768.
16. Mariette X., Matucci-Cerinic M., Pavelka K., Taylor P., van Vollenhoven R., Heatley R., et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011, 70:1895-1904. [Epub September 1, 2011].
17. Verstappen S.M., King Y., Watson K.D., Symmons D.P., Hyrich K.L. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011, 70:823-826. 10.1136/ard.2010.140822.
18. Strangfeld A., Listing J., Rau R. Pregnancy outcome after exposure to biologics: results from the German Biologics Register RABBIT [Abstract 730]. Presented at the American College of Rheumatology 71st National Meeting; Boston, MA November 6-11 2007.
19. van Vollenhoven R., Harju A., Brannemark S., Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003, 62:1195-1198.
20. van Vollenhoven R.F., Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 2005, 23:S195-S200.
21. Mariette X., Gottenberg J.E., Ravaud P., Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011, 50:222-229.
22. Altman D.G., Schulz K.F., Moher D., et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001, 134:663-694.
23. Vandenbroucke J.P., Von Elm E., Altman D.G., Gøtzsche P.C., Mulrow C.D., Pocock S.J., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297.
24. Registries for evaluating patient outcomes: a user's guide, (prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under contract no. HHSA29020050035I TO1) AHRQ publication no. 07-EHC001-1 2007, Agency for Healthcare Research and Quality, Rockville. R.E. Gliklich, N.A. Dreyer (Eds.).
25. Dixon W.G., Carmona L., Finckh A., Hetland M.L., Kvien T.K., Landewe R., et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010, 69:1596-1602. [Epub June 4, 2010].
26. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., Cöster L., et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006, 65:707-712. 10.1136/ard.2005.045872.
27. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703. 10.1136/ard.2004.030528.
28. Kobelt G., Eberhardt K., Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004, 63:4-10.
29. Watson K., Symmons D., Griffiths I., Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005, 64:iv42-iv43.
30. Hyrich K.L., Watson K.D., Silman A.J., Symmons D.P. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
31. Hyrich K.L., Symmons D.P., Watson K.D., Silman A.J. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54:1786-1794.
32. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Ustianowski A.P., Helbert M., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50:124-131.
33. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69:522-528. 10.1136/ard.2009.118935.
34. Strangfeld A., Hierse F., Rau R., Burmester G.R., Krummel-Lorenz B., Demary W., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010, 12:R5.
35. Strangfeld A., Hierse F., Kekow J., von Hinueber U., Tony H.P., Dockhorn R., et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009, 68:1856-1862.
36. Salmon-Ceron D., Tubach F., Lortholary O., Chosidow O., Bretagne S., Nicolas N., et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70:616-623. [Epub December 21, 2010].
37. Gottenberg J.E., Ravaud P., Bardin T., Cacoub P., Cantagrel A., Combe B., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632. 10.1002/art.27555.
38. Gomez-Reino J.J., Rodriguez-Lozano C., Campos-Fernandez C., Montoro M., Descalzo M.A., Carmona L. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012, 71:382-385. [Epub October 13, 2011].
39. BIOBADASER at Accessed November 9, 2011. http://biobadaser.ser.er.
40. Kvien T.K., Heiberg M.S., Lie E., Kaufmann C., Mikkelsen K., Nordvag B.Y., et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005, 23:S188-S194.
41. Lie E., van der Heijde D., Uhlig T., Mikkelsen K., Kalstad S., Kaufmann C., et al. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. Ann Rheum Dis 2011, 70:2103-2110.
42. Hetland M.L. DANBIO-powerful research database and electronic patient record. Rheumatology (Oxford) 2011, 50:69-77.
43. Hetland M.L., Christensen I.J., Tarp U., Dreyer L., Hansen A., Hansen I.T., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
44. DREAM website at Accessed November 9, 2011. http://www.dreamregistry.nl.
45. Kievit W., Fransen J., Adang E.M. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011, 50:196-203. [Epub November 14, 2010].
46. GISEA website at Accessed November 9, 2011. http://www.registrogisea.com.
47. Iannone F., Atzeni F., Biasi D., et al. Long-term survival of anti-TNF therapy in a large Italian cohort of RA patients: comparison among adalimumab, etanercept and infliximab. Ann Rheum Dis 2011, 70:255.
48. Marchesoni A., Zaccara E., Gorla R., Bazzani C., Sarzi-Puttini P., Atzeni F., et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009, 1173:837-846.
49. Caporali R., Sarzi-Puttini P., Atzeni F., Gorla R., Filippini M., Marchesoni A., et al. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010, 9:465-469.
50. Pallavicini F.B., Caporali R., Sarzi-Puttini P., Atzeni F., Bazzani C., Gorla R., et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010, 9:175-180.
51. Uitz E., Fransen J., Langenegger T., Stucki G. Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford) 2000, 39:542-549.
52. Langenegger T., Fransen J., Forster A., Seitz M., Michel B.A. Clinical quality management in rheumatoid arthritis. Z Rheumatol 2001, 60:333-341.
53. Finckh A., Simard J.F., Duryea J., Liang M.H., Huang J., Daneel S., et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006, 54:54-59.
54. Kyburz D., Gabay C., Michel B.A., Finckh A. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology (Oxford) 2011, 50:1106-1110. [Epub January 21, 2011].
55. Finckh A., Ciurea A., Brulhart L., Möller B., Walker U.A., Courvoisier D., et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?. Ann Rheum Dis 2010, 69:387-393. [Epub May 4, 2009].
56. Konttinen L., Honkanen V., Uotila T. Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 2006, 26:916-922. [Epub January 10, 2006].
57. Virkki L., Aaltonen K., Nordstrom D. Biological therapy in rheumatoid arthritis based on ten years of registry surveillance in Finland. Duodecim 2010, 126:1487-1495.
58. ATTRA website at Accessed November 9, 2011. http://attra.registry.cz.
59. Pavelka K., Forejtova S., Stolfa J., Chroust K., Buresová L., Mann H., et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009, 27:958-963.
60. Bodur H., Ataman S., Buǧdayci D.S., Rezvani A., Nas K., Uzunca K., et al. Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP. Rheumatol Int 2012, 32:169-176. 10.1007/s00296-010-1599-7.
61. Bodur H., Ataman S., Rezvani A. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011, 20:543-549.
62. Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Tarp U., et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012, 71:374-377.
63. Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Tarp U., et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70:1575-1580. 10.1136/ard.2010.148759.
64. Askling J., Baecklund E., Granath F., Geborek P., Fored M., Backlin C., et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68:648-653. [Epub May 8, 2008].